SUSPENDED

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Official Title

Exploring the Attitudes and Experiences of Patients Engaged in Buprenorphine Treatment During the COVID-19 Pandemic

Quick Facts

Study Start:2021-11-20
Study Completion:2027-03-20
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:SUSPENDED

Study ID

NCT05121428

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must be 18 years of age or older.
  2. * Participants report currently having a legal prescription for buprenorphine for opioid use disorder.
  3. * Participants must have a past or present opioid use disorder.
  4. * Participants must currently reside in the state of Massachusetts.
  5. * Participants must be able to comprehend the English language.
  1. * Unable to complete an online survey.
  2. * Unable to complete a verification step that ensures bots are not used to complete survey.
  3. * Complete a survey with no variation suggesting they did not read the survey.

Contacts and Locations

Principal Investigator

Zev Schuman-Olivier, MD
PRINCIPAL_INVESTIGATOR
Cambridge Health Alliance
Joseph Rosansky
STUDY_DIRECTOR
Cambridge Health Alliance

Study Locations (Sites)

CHA Center for Mindfulness and Compassion
Cambridge, Massachusetts, 02141
United States

Collaborators and Investigators

Sponsor: Cambridge Health Alliance

  • Zev Schuman-Olivier, MD, PRINCIPAL_INVESTIGATOR, Cambridge Health Alliance
  • Joseph Rosansky, STUDY_DIRECTOR, Cambridge Health Alliance

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-20
Study Completion Date2027-03-20

Study Record Updates

Study Start Date2021-11-20
Study Completion Date2027-03-20

Terms related to this study

Keywords Provided by Researchers

  • Opioid Use Disorder
  • Substance Use Disorders
  • Buprenorphine
  • Suboxone
  • Cannabis
  • Cigarettes
  • E-Cigarettes
  • Benzodiazepines
  • Healthcare
  • COVID-19
  • Telemedicine
  • Office-Based Opioid Treatment
  • Facebook
  • Social Media
  • Nicotine
  • Recovery

Additional Relevant MeSH Terms

  • Opioid-use Disorder
  • Acceptability of Health Care
  • Opioid-Related Disorders